Virtus ETF Advisers’s Ultragenyx Pharmaceutical RARE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Shares Change % | Capital Flow | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q1 | – | Sell |
-7,457
| Closed | -$314K | – | 577 |
|
|
2024
Q4 | $314K | Sell |
7,457
-181
| -2% | -$7.62K | 0.13% | 241 |
|
|
2024
Q3 | $424K | Hold |
7,638
| – | – | 0.2% | 197 |
|
|
2024
Q2 | $314K | Sell |
7,638
-661
| -8% | -$27.2K | 0.15% | 221 |
|
|
2024
Q1 | $387K | Buy |
8,299
+1,194
| +17% | +$55.7K | 0.21% | 199 |
|
|
2023
Q4 | $340K | Buy |
7,105
+1,033
| +17% | +$49.4K | 0.22% | 197 |
|
|
2023
Q3 | $216K | Sell |
6,072
-788
| -11% | -$28.1K | 0.13% | 239 |
|
|
2023
Q2 | $316K | Buy |
6,860
+83
| +1% | +$3.83K | 0.19% | 188 |
|
|
2023
Q1 | $272K | Buy |
6,777
+122
| +2% | +$4.89K | 0.15% | 265 |
|
|
2022
Q4 | $308K | Buy |
6,655
+1,690
| +34% | +$78.3K | 0.16% | 252 |
|
|
2022
Q3 | $206K | Buy |
4,965
+70
| +1% | +$2.9K | 0.08% | 317 |
|
|
2022
Q2 | $292K | Buy |
4,895
+345
| +8% | +$20.6K | 0.11% | 266 |
|
|
2022
Q1 | $330K | Hold |
4,550
| – | – | 0.15% | 167 |
|
|
2021
Q4 | $383K | Buy |
4,550
+100
| +2% | +$8.42K | 0.14% | 168 |
|
|
2021
Q3 | $401K | Sell |
4,450
-403
| -8% | -$36.3K | 0.18% | 175 |
|
|
2021
Q2 | $463K | Buy |
4,853
+766
| +19% | +$73.1K | 0.19% | 175 |
|
|
2021
Q1 | $465K | Buy |
4,087
+115
| +3% | +$13.1K | 0.2% | 157 |
|
|
2020
Q4 | $550K | Sell |
3,972
-4,615
| -54% | -$639K | 0.23% | 133 |
|
|
2020
Q3 | $706K | Buy |
8,587
+723
| +9% | +$59.4K | 0.37% | 103 |
|
|
2020
Q2 | $615K | Sell |
7,864
-5,910
| -43% | -$462K | 0.29% | 109 |
|
|
2020
Q1 | $612K | Sell |
13,774
-1,162
| -8% | -$51.6K | 0.25% | 150 |
|
|
2019
Q4 | $638K | Buy |
14,936
+2,818
| +23% | +$120K | 0.1% | 172 |
|
|
2019
Q3 | $518K | Sell |
12,118
-2,044
| -14% | -$87.4K | 0.1% | 179 |
|
|
2019
Q2 | $899K | Sell |
14,162
-2,223
| -14% | -$141K | 0.19% | 153 |
|
|
2019
Q1 | $1.14M | Buy |
16,385
+3,235
| +25% | +$224K | 2.42% | 4 |
|
|
2018
Q4 | $572K | Buy |
13,150
+3,709
| +39% | +$161K | 0.1% | 59 |
|
|
2018
Q3 | $721K | Buy |
9,441
+647
| +7% | +$49.4K | 0.07% | 73 |
|
|
2018
Q2 | $676K | Sell |
8,794
-8,189
| -48% | -$629K | 0.6% | 110 |
|
|
2018
Q1 | $866K | Buy |
16,983
+9,090
| +115% | +$464K | 0.75% | 63 |
|
|
2017
Q4 | $366K | Buy |
7,893
+2,550
| +48% | +$118K | 0.46% | 72 |
|
|
2017
Q3 | $285K | Buy |
5,343
+488
| +10% | +$26K | 0.04% | 132 |
|
|
2017
Q2 | $302K | Buy |
4,855
+883
| +22% | +$54.9K | 0.05% | 121 |
|
|
2017
Q1 | $269K | Buy |
3,972
+381
| +11% | +$25.8K | 0.05% | 152 |
|
|
2016
Q4 | $252K | Sell |
3,591
-459
| -11% | -$32.2K | 0.08% | 139 |
|
|
2016
Q3 | $287K | Hold |
4,050
| – | – | 0.14% | 104 |
|
|
2016
Q2 | $198K | Buy |
4,050
+1,646
| +68% | +$80.5K | 0.15% | 135 |
|
|
2016
Q1 | $152K | Buy |
+2,404
| New | +$152K | 0.21% | 118 |
|